Dr Lipson continues his discussion as he highlights significant results from the NADINA trial. Discuss the data presented at the 2024 ASCO Annual Meeting on the phase 3 NADINA trial (NCT04949113) of ...
The C-POST trial showed a disease-free survival benefit with adjuvant Libtayo for high-risk cutaneous squamous cell carcinoma, potentially influencing future standard care. Immunotherapy remains the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback